In tumor subgroup, high expression of CCND2 predicted low risk of cancer progression (HR = 0.28, 95% CI: 0.12‐0.64, P = 0.903) in NSCLC patients, while no significant association was found in other tumor types (HR = 1.69, 95% CI: 0.22‐13.16, P < 0.001) (Figure 4F). This evidence concerns the gene CCND2 and neoplasm.